| Term 
 
        |     two main components of pain |  | Definition 
 
        | 1. physical (acute/chronic, nociceptive/neuropathic, somatic/visceral)     2. psychological (memory, fear, anticipation, depression) |  | 
        |  | 
        
        | Term 
 
        |     two classes of pharmacologic analgesics |  | Definition 
 
        | 1. Narcotics (opioids)     2.Non-Narcotic analgesics (NSAIDs etc.) |  | 
        |  | 
        
        | Term 
 
        |     Opioid effects on both main aspects of pain |  | Definition 
 
        | physiological threshold for pain percpetion raised   affective response (psychological reaction) altered (often producing euphoria or disphoria) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Thalamus Limbic System(amygdala, hippocampus, fornix, etc.) Brain Stem Spinal Cord--spinothalamic tracts especially, respond to endogenous and exogenous opioids, targeted by intrathecal or epidural opioids to cause analgesia--pre-synaptic opioid receptors inhibit neurotransmitter release while post-synaptic opioid receptors inhibit AP propagation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | enkephalins (from proenkephalins) endorphins (from pro-opiomelanocortin POMC) dynorphins (from prodynorphin)   peptide neurotransmitters, same properties as exogenous opioids (analgesic effects, blocked by naloxone, act on opioid receptors in CNS)   basis for pain releif using acupuncture |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 7 transmembrane domain G protein coupled receptors (GPCRs) distributions of subtypes vary throughout CNS   mu (most important for analgesia)   kappa (prevalent in spinal cord)   delta   sigma (not a true opioid receptor though some opioids cross react with sigma receptors) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | most important for pain control binds morphine   GPCR which when stimulated may produce analgesia, euphoria, sedation, physical and psychological dependence, respiratory depression (hypoxia) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | widely distributed in spinal cord   GPCR which when stimulated may produce dysphoria (opposite of euphoria), analgesia, and sedation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | prototypic exogenous opioid derived from poppies or synthesized in labs full mu receptor agonist--binds domains of receptor embedded in plasma membrane in addition to the N terminal binding site for endogenous opioids maximum analgesic effect euphoria, nausea/vomiting, mental clouding, antitussive, bronchoconstriction, respiratory depression, miosis, urinary retention, gonadotropin release inhibition, vascular dilation (orthostatic hypotension), constipative/antidiarrheal low oral bioavailability active metabolite (analgesic and possibly nephrotoxic action)=morphine-6-glucuronide, excreted in urine (primary method of elimination) induces tolerance (cross tolerance w/other opioids) and physical dependance, high abuse potential withdrawl/abstinence syndrome possible low lipid solubiliby (hard to cross BBB)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | progressively higher doses required to achieve same effect   most opioid have complete or incomplete cross-tolerance with other opioids   tolerance to opioids is always pharmacodynamic (receptors downregulated or endocytosed in presence of drug) NOT metabolic (induction of liver CYPs etc.) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | patient undergoes withdrawl/abstinence syndrome when opioid is removed from system or blocked (naloxone induces withdrawl in an opioid dependent person)   develops during long-term opioid use   not equivalent to addiction     |  | 
        |  | 
        
        | Term 
 
        |         Adverse effects of Opioids |  | Definition 
 
        | respiratory depression (especially in opioid niaive pts!) constipation (decreased peristalsis) nausea & vomiting (stimulation of chemorecptor trigger zone) abuse potential (euphoria, dependence, tolerance) confusion/lethargy/apathy/sedation bronchoconstriction (directly and indirectly via histamine release, especially morphine) miosis urinary retention (increased ADH release & direct action on bladder destrusor muscle) hormonal disturbances (inhibits gonadotropin release) orthostatic hypotension (histamine release, depressed adrenergic and vasomotor tone)       |  | 
        |  | 
        
        | Term 
 
        |         Clinical uses for opioids |  | Definition 
 
        | Analgesia--typically for moderate or severe pain levels     Antitussive (rare use these days)   Antidiarrheal |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 1.miosis   2.respiratory depression   3.coma   treat immediately with Naloxone=Narcan (opioid receptor antagonist) until triad of symptoms reverses     |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Euphoria (most common change)     Dysphoria also possible (especially kappa agonists) |  | 
        |  | 
        
        | Term 
 
        |       Opioid stimulated Nausea and Vomiting |  | Definition 
 
        |     Chemoreceptor trigger zone irritation |  | 
        |  | 
        
        | Term 
 
        |         Respiratory Depression caused by Opioids |  | Definition 
 
        | opioids decrease brainstem response to CO2 levels (the central drive to breathe)   bronchoconstriction: direct action on smooth muscle cell recpetors   some opioids like morphine also cause histamine release   cough reflex suppression--may be beneficial (antitussive) or harmful (airway obstructing) but typically occurs at doses below analgesic threshold |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | pinpoint pupil   common sign of overdose |  | 
        |  | 
        
        | Term 
 
        |       Urinary Retention caused by Opioids |  | Definition 
 
        | increased ADH release from pituitary-->water reabsorption from colleting ducts in kidneys     direct inhibitory action on detrusor muscle of bladder |  | 
        |  | 
        
        | Term 
 
        |         Hormonal effects of Opioids |  | Definition 
 
        | decreased release of LH and FSH may disrupt fertility in males and females (transient) menstrual irregularities in females |  | 
        |  | 
        
        | Term 
 
        |         Cardiovascular effects of Opioids |  | Definition 
 
        | peripheral vascular dilation-->postural hypotension   caused by histamine release and depressed adrenergic tone |  | 
        |  | 
        
        | Term 
 
        |     Metabolism and Excretion of Morphine |  | Definition 
 
        | Metabolism: glucuronide conjugation in liver   Excretion: as glucuronide via the urine |  | 
        |  | 
        
        | Term 
 
        |         Opioid abstinence or withdrawl sydrome |  | Definition 
 
        | begins 8-12 hours after last morphine dose and peaks at 36-72 hours (varies with half-life for other opioids)   delayed onset and less severe for long acting opioids   diarrhea, vomiting, chills, fever, lacrimation, rhinorrhea, tremor, kicking/twitching   naloxone to induce (test for heroin addiction or physical depedence to any opioid)   clonidine to treat |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | centrally active alpha 2 receptor agonist   decreases norepinephrine release in brain   used to treat symptoms of opioid withdrawl |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | orally active opioid analgesic w/approximately 1/10th potency of morphine   used for mild-moderate pain, often in combo. with aspirin, acetaminophen, or NSAIDs   antitussant activity   better lipid solubility vs. morphine--crosses BBB   metabolized by CYP2D6 (pharmacogenetics:poor metabolizers get little effect) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | opioid drug (diacetylmorphine)   variable oral absorption, parenteral absorption better   high lipid solubility--crosses BBB   IV illicit drug in the U.S.; used medically in some countries |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | opioid analgesic with similar potency and efficacy as morphine   but with higher oral availability   used for severe pain   frequently abused--addicts grind this up for a faster high   found in Oxycontin, Percocet (w/acetaminophen), and Percodan (w/aspirin)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | opioid analgesic with efficacy comparable to morphine but ten times more potent   for severe pain   high oral bioavailability   high abuse potential   (Dilaudid)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | opioid with LITTLE ANALGESIC ACTIVITY   primary use as an EMETOGENIC agent--stimulates vomiting by irritating the CTZ   can still cause respiratory depression like most opioids (titrate carefully and watch patient closely) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | opioid with very LITTLE ANALGESIC ACTION   mainly used as an ANTITUSSANT   low addiction potential   less drowsiness and GI upset vs. codeine   a.k.a. Romilar   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Demerol   short-acting opioid analgesic   synthetic, orally active, for moderate-severe pain   1/10 the potency of morphine   popular for pain relief for women in labor   according to ICM becoming less popular in hospitals due to side effects (seizures + common opioid adverse effects)   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a Sublimaze   synthetic opioid analgesic 80X the potency of morphine   short-acting, t1/2 only 20 minutes   highly lipid soluble, crosses BBB, action terminated mainly by resdistribution between body compartments (like thiopental)   oral, sublingual, or IV    for severe pain, anesthetic induction, may be sole anesthetic in cardiac surgery, also used as an antipsychotic (neuroleptic) in combo. w/droperidol=innovar     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | short-acting synthetic opioid analgesic/anesthetic similar to fentanyl     causes pain releif and muscle relaxation--good for outpatient surgery |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Sufenta   short-acting synthetic opioid analgesic/anesthetic similar to fentanyl     causes pain releif and muscle relaxation--good for outpatient surgery |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Dolophine   orally active synthetic opioid analgesic w/action and potency comparable to morphine   long-acting, t1/2 is about 15 hours   used for chronic pain and to treat opioid addiction (methadone maintenance)   causes less euphoria than the commonly abused opioids (heroin, morphine, oxycodone, etc.) but prevents withdrawl in addicts |  | 
        |  | 
        
        | Term 
 
        |         LAAM (L-alpha-acetyl-methadol) |  | Definition 
 
        | a.k.a. Orlaam   long-acting sythetic orally active opioid analgesic (mu agonist)   methadone cogener used for heroin addiction treatment (reduces craving) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a Darvon   orally active synthetic opioid analgesic comparable to codeine in potency and use   for mild-moderate pain   usually combined with aspirin or acetaminophen |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | combined with atropine to form Lomotil   oral synthetic opioid used as an ANTI-DIARRHEAL   NOT for analgesia   some abuse potential--offset by coformulation with atropine (unpleasant antimuscarinic effects at high doses) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Immodium   OTC oral opioid drug used as an ANTIDIARRHEAL   poorly absorbed from GI tract, acts directly on intestinal musculature to inhibit motility   NOT an analgesic   low penetrantion to CNS--reduced abuse potential compared to diphenoxylate though equally effective in countering diarrhea |  | 
        |  | 
        
        | Term 
 
        |         Treatment of Opioid Overdose |  | Definition 
 
        | (CNS depression/coma, repiratory depression, miosis)   1.Restore respiration, estabilish airway if necessary, give supplemental but not pure O2 (CO2 stimulates the stunned central respiratory center)   2.Give Naloxone (antagonist at all opioid receptors) 4-8 mg IV or IM until symptoms reverse   3.Observe patient closely and readminister naloxone as needed (shorter half life vs. most opioid drugs) |  | 
        |  | 
        
        | Term 
 
        |         Classes of Drugs that interact Additively with Opioids to cause CNS or Respiratory Depression |  | Definition 
 
        | Sedatives Sedative-hypnotics Ethanol Monoamine Oxidase Inhibitors (MAOIs) Tricyclic antidepressants Tranquilizers |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Naloxone and Naltrexone   block all effects of opioids (analgesia, euphoria/dysphoria, respiratory depression, GI upset/constipation, etc.)   used to treat opioid overdose, diagnose physical dependence on opioids esp. in context of addiction, control compulsive use in addiction treatment  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Narcan   short-acting pure opioid antagonist, IV or IM   competative antagonism of all opioids (including the endogenous ones) at all opioid receptors (mu, kappa, delta)   t1/2 of 1-4 hours (monitor overdose patients!)   used to treat opioid OD, may trigger withdrawl--use to diagnose dependence |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Trexan   long-acting competative opioid antagonist, t 1/2 is about 24 hours, oral drug   blocks endogenous and exogenous opioid action   used to decrease cravings in programs for heroin and alcohol addiction (reduces compulsive use by eliminating endogenous opioid rush associated with alcohol abuse)   used to diagnose physical dependence on opioids--precipitates withdrawl syndrome   not as good as naloxone for emergency treatment of opioid OD b/c long-acting/slow |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Talwin   mixed opioid agonist/antagonist used for analgesia in mild-moderate pain   kappa agonist--effective spinal analgesia   weak mu ANTagonist--counters morphine analgesia (but not respiratory depression) and induces withdrawl in the morphine-dependent   less severe respiratory depression and withdrawl syndrome vs. morphine   dysphoria and hallucinations at higher doses (from cross-stim. of sigma "not-an-opioid-receptor" receptors) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Nubain   kappa opioid receptor agonist mu opioid receptor ANTagonist--induces morphine withdrawl   analgesic for moderate to severe pain with limited respiratory depression and low risk of mild dependence   low incidence of psychotomimetic effects (dysphoria/hallucinations) b/c does not stim. sigma R's   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a Stadol  similar to Nalbuphine   kappa opioid receptor agonist mu opioid receptor ANTagonist--induces morphine withdrawl   analgesic for moderate to severe pain with limited respiratory depression and low risk of mild dependence   low incidence of psychotomimetic effects (dysphoria/hallucinations) b/c does not stim. sigma R's   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | a.k.a. Buprenex   mixed mu opioid receptor agonist/antagonist kappa ANTagonist   analgesic for moderate-severe pain slow onset, long-lasting   lower risk of repiratory depression and withdrawl syndrome vs. morphine (still causes euphoria and miosis though)   induces withdrawl in people severely dependent on morphine   may be alternative to methadone as maintenance drug tx for opioid addicts (reduces craving)     |  | 
        |  |